Jump to content

New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-Stage Lung Cancer


Recommended Posts

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentriq ® (atezolizumab) for people with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1≥1%. Data from the IMpower010 trial were published simultaneously in The Lancet. In IMpower010, treatment with Tecentriq, following surgery and chemotherapy, reduced the risk of disease recurrence or death (DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA NSCLC whose tumors express PD-L1≥1%, compared with best supportive care (BSC). Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.

The Genentech press release announcing new data from the Phase III IMpower010 study of adjuvant Tecentriq in early-stage NSCLC crossed the wire this morning at 6:05 a.m. PT, timed with the 2021 ESMO Presidential Symposium presentation and simultaneous publication in The Lancet. The full release can be viewed here: https://www.gene.com/media/press-releases/14929/2021-09-20/new-phase-iii-data-support-the-benefit-o

Link to comment
Share on other sites

  • 2 weeks later...


This topic is now archived and is closed to further replies.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.